Karen J. Ferrante

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 997 citations

A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

Pedro Sanz-Altamira, Karen J. Ferrante, Roger L. Jenkins et al. · Cancer · 1998 · 86 citations · Full text

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig et al. · Clinical Cancer Research · 2015 · 79 citations

Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer

Mary-Ellen Taplin, Emmanuel S. Antonarakis, Karen J. Ferrante et al. · European Urology · 2019 · 64 citations

Urology, Medicine, Hormonal Receptor +8

A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors

Daniel D. Karp, Karen J. Ferrante, Thomas G. Tensfeldt et al. · Lung Cancer · 2000 · 58 citations

Medicine, Tyrosine Kinase, Receptor Tyrosine Kinase +7